# Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

> **NCT01856283** · PHASE2 · COMPLETED · sponsor: **Niguarda Hospital** · enrollment: 87 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic-Phase

## Interventions

- **DRUG:** Nilotinib 300mg BID

## Key facts

- **NCT ID:** NCT01856283
- **Lead sponsor:** Niguarda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2020-07
- **Final completion:** 2021-01
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856283, "Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01856283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*